Supernus Pharmaceuticals, Inc. (SUPN)
45.11
-0.74
(-1.61%)
USD |
NASDAQ |
Aug 24, 16:00
45.11
0.00 (0.00%)
After-Hours: 20:00
Supernus Pharmaceuticals Enterprise Value : 2.292B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 2.292B |
| August 21, 2026 | 2.335B |
| August 20, 2026 | 2.428B |
| August 19, 2026 | 2.491B |
| August 18, 2026 | 2.520B |
| August 17, 2026 | 2.476B |
| August 14, 2026 | 2.476B |
| August 13, 2026 | 2.411B |
| August 12, 2026 | 2.452B |
| August 11, 2026 | 2.395B |
| August 10, 2026 | 2.406B |
| August 07, 2026 | 2.439B |
| August 06, 2026 | 2.388B |
| August 05, 2026 | 2.397B |
| August 04, 2026 | 2.184B |
| August 03, 2026 | 2.344B |
| July 31, 2026 | 2.264B |
| July 30, 2026 | 2.321B |
| July 29, 2026 | 2.377B |
| July 28, 2026 | 2.444B |
| July 27, 2026 | 2.401B |
| July 24, 2026 | 2.355B |
| July 23, 2026 | 2.413B |
| July 22, 2026 | 2.398B |
| July 21, 2026 | 2.452B |
| Date | Value |
|---|---|
| July 20, 2026 | 2.426B |
| July 17, 2026 | 2.462B |
| July 16, 2026 | 2.472B |
| July 15, 2026 | 2.444B |
| July 14, 2026 | 2.382B |
| July 13, 2026 | 2.422B |
| July 10, 2026 | 2.487B |
| July 09, 2026 | 2.504B |
| July 08, 2026 | 2.602B |
| July 07, 2026 | 2.457B |
| July 06, 2026 | 2.416B |
| July 02, 2026 | 2.463B |
| July 01, 2026 | 2.426B |
| June 30, 2026 | 2.373B |
| June 29, 2026 | 2.373B |
| June 26, 2026 | 2.375B |
| June 25, 2026 | 2.254B |
| June 24, 2026 | 2.277B |
| June 23, 2026 | 2.238B |
| June 22, 2026 | 2.238B |
| June 18, 2026 | 2.232B |
| June 17, 2026 | 2.186B |
| June 16, 2026 | 2.186B |
| June 15, 2026 | 2.202B |
| June 12, 2026 | 2.234B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Indivior Pharmaceuticals, Inc. | 4.556B |
| Pfizer Inc. | 211.20B |
| Amphastar Pharmaceuticals, Inc. | 1.311B |
| Collegium Pharmaceutical, Inc. | 1.957B |
| Bristol Myers Squibb Co. | 171.44B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -58.37M |
| Revenue (Quarterly) | 219.06M |
| Total Expenses (Quarterly) | 277.43M |
| EPS Diluted (Quarterly) | -1.005 |
| Gross Profit Margin (Quarterly) | 72.88% |
| Profit Margin (Quarterly) | -26.65% |
| Earnings Yield | -4.24% |
| Normalized Earnings Yield | -2.469 |